SLC16A1 and familial pancreatic carcinoma: Taken together, our findings, including the IHC pattern, demonstrated that SLC16A1 and SLC16A3 could be potentially ideal prognosis makers and therapy targets for patients with pancreatic cancer as treatment strategies.